Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab
Carcinoma, Non-Small-Cell Lung
Disease-Free Survival
Drug Therapy, Combination
Europe
Female
Follow-Up Studies
Humans
Lung Neoplasms
Male
Middle Aged
Prospective Studies
Survival Rate
Time Factors
Treatment Outcome
United States
Vascular Endothelial Growth Factor A